There's good news and bad news for Moderna (NASDAQ: MRNA) investors. The good news is that shares of the messenger RNA (mRNA) vaccine maker have skyrocketed over 1,100% since the beginning of 2020. The bad news is that Moderna has given up a lot of its gains with the stock plunging close to 50% below its high from earlier this year.
But is this beaten-down vaccine stock a buy now? Two Motley Fool contributors have different takes on Moderna.
Image source: Getty Images.
Source Fool.com